Background: Immune-related adverse events (irAEs) are inflammatory side effects, which
can occur during immune-checkpoint (s) inhibitors (ICIs) therapy. Steroids are the first-line …

Background Immune checkpoint inhibitors have transformed the treatment landscape of
cancer treatment, but only a fraction of patients responds to treatment, leading to an …

Background Corticosteroids (CS) are the mainstay of immune-related adverse effect (irAE)
management, as well as for other indications in cancer treatment. Previous studies …

12083 Background: The detrimental impact of steroids (ST) on patients receiving immune
checkpoint inhibitors (ICI) has been described in several studies. However, the influence of …

Objectives Obesity and hypercholesterolemia are linked to unfavor clinical outcomes.
Recent studies declared the paradox that high body mass index (BMI) and serum …

Previous studies have suggested a negative impact of steroids on the efficacy of immune
checkpoint inhibitors (ICI), but how this effect is modulated by the dosage and time of …

e15234 Background: Corticosteroids are commonly used for management of cancer-related
symptoms or immune-related adverse events (irAEs) in cancer patients treated with immune …

Background Anti-PD-1 immune checkpoint blockade is approved for first-line treatment of
recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), but few patients …

Introduction Cancer is a major global health concern, and immune checkpoint inhibitors
(ICIs) offer a promising treatment option for cancer patients. However, the efficacy of ICIs can …

e14694 Background: Immune checkpoint inhibitors (ICI) have dramatically extended survival
in numerous malignancies, but many patients treated with ICIs experience severe immune …